The further back you go in time, the worse the overall picture becomes for Generex Biotechnology Corp (OTC:GNBT) stock. Used to trade on the NASDAQ, used to trade above $15 per share. All in the past now, these days, it is either a small decline, or a sharp crash, but a period of steady decline overall. Last Friday is a good example. More than 4 million shares exchanging hands. Stock price closing at $0.14 per share, making up for a 20% decrease for the session. Shorters also had their share of the action, as short-selling activity reached almost 1 million shares for the day. The thing is, there was no immediate catalyst for this trading hype. There is one today, however.[BANNER]
Generex just released an announcement, which is set to clarify some facts regarding the company and especially the negative development on the stock market last Friday. A crash, which the press release attributes to blog posts, one in particular. An interesting PR, yet not unusual. Last year, similar events led to a lawsuit. A lawsuit for $250 million.
All in all, facts that contribute to an interesting story, but not exactly the ones shareholders might be looking for. The steady decline in question, the prevailing negative opinions all over forums on the Internet are all facts that hardly help this company achieve its milestones. It is high time for a catalyst to appear which could reverse this negative trend. Whether this could happen, however, is a question of uncertainty, yet to find its answer.
